Methods. We adapted a previously published forecasting model to estimate the reduction in OM cases in Canada since the introduction of PCVs in all routine provincial programs in 2005 through 2015 (the last year complete data were available). The impact of PCV on OM was modeled and compared with pre-PCV incidence to estimate net impact of the vaccine. We assumed that 90% of OM episodes were treated with an initial Abx given routine practice. All data were sourced from the published literature.
Results. Over 10 years, PCVs were estimated to avert 3.7 million cases of OM in Canada. This corresponded to an estimated reduction of 3.3 million Abx, or 0.96 Abx avoided per infant vaccinated with PCV.
Conclusion. PCVs have had a significant public health impact on reducing the burden of disease and Abx. While most of the PCV impact on reduction of Abx is due to reduction in OM cases, additional Abx reduction from prevention of other invasive and noninvasive pneumococcal diseases is of importance. Further research is necessary to understand the additional net benefit of reducing antibiotics across the disease spectrum given that reductions in net prescribing could avert further downstream resistance by other pathogens. Methods. A total of 1,821 Spn isolates (<6 years old) from sterile fluids were received at NRL between January 2010 and December 2016 from 150 hospitals, 24 provinces and Buenos Aires city; 1029 (56.5%) <2 years old. Isolates were serotyped by Quellung, MICs were performed by agar dilution (CLSI) and resistance genes by PCR. Diagnosis: pneumonia (42%), meningitis (28%), sepsis (16%), other (14%). Eighty of 1,029 (7.8%) Spn were serotype 24. Three periods were defined: pre-PCV13 (2010-2011), transitional (2012) and post-PCV13 (2013) (2014) (2015) (2016) .
Results. Among 1,029 Spn isolated in <2 years old, PCV13 serotypes decreased from 86.4% (pre-PCV13) to 33.7% (post-PCV13) related to serotypes: 14, 6A, 6B and 5 (P < 0.05). Non-PCV13 serotypes increased from 13.6% (pre-PCV13) to 66.3%% (post-PCV13), mainly due to serotypes 24, 12F and 23B (P < 0.05). Among 80 serotype 24 Spn, 44 (55%) were <1 years old. Serotype 24 increased from 2.1 to 16.2% (pre-/post-PCV13), and ranks first since 2013. Antimicrobial nonsusceptibility (NS) among serotype 24 in pre-/post-PCV13 periods was: penicillin (PEN) (MIC ≥0.12 µg/ mL) 70/91.2%, cefotaxime (MIC ≥ 1 µg/mL) 0/1.5%, erythromycin (ERY) 70/89.7%, tetracycline (TET) 60/83.8% and trimethoprim-sulfamethoxazole (SXT) 60/89.7%. NS to meropenem, chloramphenicol, levofloxacin, rifampicin, ceftaroline, and vancomycin was no detected. 97.1% of ERY-NS isolates carried ermB and 2.9% mefA genes. All the TET-NS isolates carried the tetM gene. Multidrug resistance to PEN, ERY, TET, and SXT increased from 50% in pre-PCV13 to 82% in post-PCV13 period (P < 0.05).
Conclusion. Serotype 24 represents the main non-PCV13 serotype in <2 years old with IPD after the introduction of PCV13. We observed an increase in prevalence and multidrug resistance in post-PCV13 period. Our results suggest that this emerging serotype could represent a real threat among pneumococcal disease in the near future.
Disclosures. All authors: No reported disclosures. Methods. Cases of invasive pneumococcal disease (IPD) in children <18 years of age were detected through an enhanced surveillance system in MA since 2001. All cases in children and Streptococcus pneumoniae (SP) isolates, when available, are submitted to Department of Public Health (MDPH) and parents/physicians are interviewed for confirmation of demographic and clinical data. All available isolates are confirmed as SP, serotyped by Quellung reaction.
Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
Results. There were 351 IPD cases in MA children from April 1, 2010 to September 31, 2017, and 36 (10.3%) were in infants <6 months; 42 (12.0%) in children between 6 and 12 months; 63 (18.0%) in toddlers 12-24 months; 102 (29.1%) in children aged 2-5 years, and 108 (30.8%) were in children aged ≥5 years. Incidence of IPD declined to 6.8/10 5 children (95% CI 2.6-11.1) in 2015/2016 period which represents a 72.1% decline compared with 2010/2011 (24.4/10 5 , 95% CI 16.3-32.5) (figure). However, in 2016/2017, IPD incidence increased to 10.4/10 5 children (95% CI 5.2-15.7). The most common clinical presentation was bacteremia (62.9%), followed by pneumonia (30.5%) and CNS disease (6.6%). Among, 103 (32.6%) children with ≥1 comorbidity, asthma (13.2%), hematologic malignancy (12.1%), prematurity (9.9%) and sickle cell disease (9.9%) were the most common comorbidities. He overall mortality rate was 5.1%. Isolates from 308 (89.3%) were available for serotyping; vaccine serotypes (VST) were identified in 106 (33.3%) IPD cases [19A (46.2%), 7F (19.9%), 3 (17.9%), 19F (10.4%), 6A (2.8%), 14, 18C, 5 (0.9% each). Serotypes 15BC (13.7%), 22F (12.6%) and 33F (11.8%) were the most common nonvaccine serotypes (NVST).
Conclusion. Invasive pneumococcal disease identified in the post-PCV13-era is primarily caused by NVSTs, specifically serotypes 15BC, 33F and 22F; and disproportionately observed in children with comorbid conditions. Continued surveillance is necessary to determine the impact of PCV13, as well as track potential changes in disease incidence and character due to NVST.
